Answers are grounded in this paper and cite their sources.
Purpose of review In most Western countries, prostate cancer early detection is not organized but left to “shared decision-making” between individual men and their physicians. We assess whether this approach can bear the ethical weight assigned to it and consider what respect for persons requires instead. Recent findings A recent appraisal of the preference-sensitivity premise underlying informed-choice policies found it widely asserted in the guideline literature but rarely substantiated; the decision models it identified favour screening across the plausible range of individual utilities. Mandated conversations are incompletely delivered, and qualitative work shows that invited men expect the health system to make a considered, trustworthy offer rather than to hand them a dossier. Meanwhile the pathway itself has changed: magnetic resonance imaging before biopsy roughly halves the detection of clinically insignificant cancer, with no statistically significant difference in the detection of significant disease (equivalence has not been shown, and mortality outcomes remain under evaluation), and European policy and the PRAISE-U pilots now frame early detection as an organized, evaluated programme. Summary We argue that the decision to be screened is, for most men, not materially preference-sensitive, and that its benefit–harm balance depends largely on programme design. An informed decision is owed to everyone invited; shared decision-making belongs where preferences genuinely change the right answer, at biopsy, treatment and the decision to stop. Choice without organization is not autonomy but abandonment.
No takes yet. Share an insight, caveat, or question.
Shariat et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: